전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-3 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Melanoma (Skin) · Melanoma (Skin)

#MelanomaSkin#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Recruiting
CGTLimited DatastaleBioceltech Therapeutics, Ltd.Phase 1

BT-007 CD7 CAR-T cells (BT-007 CD7 CAR-T cells)

T Cell Lymphoblastic Lymphoma · T Cell Lymphoblastic Lymphoma

#TCellLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Bamlanivimab (Bamlanivimab)

COVID-19 · COVID-19

#COVID-19#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleNovartisPhase 3

Simulect (Basiliximab, Basiliximab (Simulect))

Organ Transplantation, Renal Transplantation · Organ Transplantation, Renal Transplanta

#OrganTransplantationRenalTranspl#Antibody#Phase3#monoclonal-antibody#OrganTransplantation+2
Trials 1Status Active
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages)

AL Amyloidosis; Amyloidosis · AL Amyloidosis

#ALAmyloidosis#ADC#Phase2#antibody-drug-conjugate#Amyloidosis+1
Trials 1Status Recruiting
AntibodyLimited DatastaleFujian Medical UniversityApproved

Bemosuzumab (Bemosuzumab)

Thyroid Neoplasms · Thyroid Neoplasms

#ThyroidNeoplasms#Antibody#Approved#monoclonal-antibody#Fujian
Trials 1Status Recruiting
CGTAAVLimited DatastaleNeurologix, Inc.Phase 2

Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)

Parkinson's Disease · Parkinson's Disease

#ParkinsonsDisease#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleSanofiPreclinical

dupilumab, mepolizumab and benralizumab according to their marketing approval (Biologic treatments available in CRSwNP, Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval))

Chronic Rhinosinusitis With Nasal Polyps · Chronic Rhinosinusitis With Nasal Polyps

#ChronicRhinosinusitisWithNasalPo#Antibody#Preclinical#monoclonal-antibody#Sanofi
Trials 1Status Recruiting
AntibodyLimited DatastaleHanyang University Seoul Hospit…Approved

Biological: Etanercept and its biosimilars (Biological: Etanercept and its biosimilars)

Ankylosing Spondylitis; Axial Spondyloarthritis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Approved#monoclonal-antibody#AxialSpondyloarthritis+1
Trials 1Status Active
ADCLimited DatastaleAmgenPhase 2

Blinatumomab and Inotuzumab Ozogamicin (Blinatumomab and Inotuzumab Ozogamicin)

Acute Lymphoblastic Leukemia; Immunotherapy · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#ADC#Phase2#antibody-drug-conjugate#Immunotherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBiocon Biologics UK LtdPhase 3

Bmab1200 (Bmab1200)

Moderate to Severe Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoria

#ModeratetoSevereChronicPlaquePso#Antibody#Phase3#monoclonal-antibody#Biocon
Trials 1Status Active
AntibodyLimited DatastaleBiocon Biologics UK PLCPhase 1

Bmab1800 (Bmab1800)

Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) · Adult Patients With Stage IIB, IIC, and

#AdultPatientsWithStageIIBIICand#Antibody#Phase1#monoclonal-antibody#AdultPatientsWithStageIIB+3
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of California, San F…Phase 3

Bococizumab (Bococizumab)

Dyslipidemia; Cardiovascular Disease · Dyslipidemia

#Dyslipidemia#Antibody#Phase3#monoclonal-antibody#CardiovascularDisease+1
Trials 1Status Discontinued
AntibodyLimited DatastaleProvidence Health & ServicesPhase 2

Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG, Bortezomib, Thymoglobulin, Rituximab, Gamimune N,, Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis)

Heart Transplantation · Heart Transplantation

#HeartTransplantation#Antibody#Phase2#monoclonal-antibody#Providence
Trials 1Status Discontinued
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 1

brentuximab vedotin (Adcetris, Brentuximab vedotin and rifampicin)

Hodgkin Lymphoma; Anaplastic Large-cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase1#antibody-drug-conjugate#AnaplasticLarge-cellLymphoma+1
Trials 1Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
CGTLimited DatastaleZhejiang UniversityPhase 1

C-CAR031 (C-CAR031)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

C-CAR066 (C-CAR066)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active

24 / 51 pages

← PreviousNext →